Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?

Core Viewpoint - Investors are expected to focus on Amicus Therapeutics' sales performance and updates regarding its merger with BioMarin Pharmaceutical during the upcoming earnings report for Q4 and full-year 2025 [1][6]. Sales Performance - The Zacks Consensus Estimate for Q4 sales is $179.9 million, with earnings expected at 13 cents per share [1]. - Galafold sales are projected to be a key revenue driver, with estimates for Q4 sales at $157 million, reflecting strong demand and compliance [8]. - The combination therapy Pombiliti + Opfolda is also expected to contribute positively to revenues, following its FDA approval in September 2023 [7][8]. Earnings Estimates - The Zacks Consensus Estimate for 2025 EPS is stable at 35 cents, while the estimate for 2026 is 65 cents [2]. - The earnings surprise history shows Amicus has beaten earnings expectations only once in the last four quarters, with an average negative surprise of 20.21% [4]. Merger Details - BioMarin has agreed to acquire Amicus for $14.50 per share, totaling $4.8 billion, with the deal expected to close in Q2 2026 [9][10]. - Post-acquisition, BioMarin will add Galafold and Pombiliti to its portfolio and gain exclusive U.S. rights to the late-stage drug DMX-200 [10]. Stock Performance - Amicus shares have increased by 104.9% over the past six months, outperforming the industry growth of 23.8% [11]. - The stock is currently trading at a price-to-sales (P/S) ratio of 7.42, which is higher than the industry average of 2.46, but below its five-year mean of 8.72 [14][15]. Investment Outlook - The acquisition by BioMarin is seen as a potential catalyst for value realization beyond organic sales growth, with optimism surrounding the strong sales of marketed products [16]. - Despite concerns regarding competition and reliance on Galafold, the company is expected to maintain growth potential, making it advisable for current investors to hold their positions [17][19].